JP2010526800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526800A5 JP2010526800A5 JP2010506999A JP2010506999A JP2010526800A5 JP 2010526800 A5 JP2010526800 A5 JP 2010526800A5 JP 2010506999 A JP2010506999 A JP 2010506999A JP 2010506999 A JP2010506999 A JP 2010506999A JP 2010526800 A5 JP2010526800 A5 JP 2010526800A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- group
- substituents
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052760 oxygen Inorganic materials 0.000 claims 52
- 125000000217 alkyl group Chemical group 0.000 claims 45
- 125000001424 substituent group Chemical group 0.000 claims 45
- 229910052717 sulfur Inorganic materials 0.000 claims 37
- 229910052757 nitrogen Inorganic materials 0.000 claims 34
- 125000005842 heteroatom Chemical group 0.000 claims 33
- 229910052736 halogen Inorganic materials 0.000 claims 31
- 150000002367 halogens Chemical class 0.000 claims 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims 27
- 125000000623 heterocyclic group Chemical group 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 23
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- -1 NR c Inorganic materials 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000002015 acyclic group Chemical group 0.000 claims 12
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 125000001153 fluoro group Chemical group F* 0.000 claims 12
- 125000004432 carbon atom Chemical group C* 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 8
- 125000002619 bicyclic group Chemical group 0.000 claims 8
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 7
- 125000002252 acyl group Chemical group 0.000 claims 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 7
- 229930195733 hydrocarbon Natural products 0.000 claims 7
- 150000002430 hydrocarbons Chemical class 0.000 claims 7
- 125000002950 monocyclic group Chemical group 0.000 claims 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 5
- 150000001204 N-oxides Chemical class 0.000 claims 5
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000012453 solvate Substances 0.000 claims 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- MIXJMLGVZCBRIX-UHFFFAOYSA-N 2,5-diphenyl-1,3-oxazole-4-carboxamide Chemical compound NC(=O)C=1N=C(C=2C=CC=CC=2)OC=1C1=CC=CC=C1 MIXJMLGVZCBRIX-UHFFFAOYSA-N 0.000 claims 3
- JCNYVYGICSWKQM-UHFFFAOYSA-N 2-(4-methylphenyl)-5-phenyl-1,3-oxazole-4-carboxamide Chemical compound C1=CC(C)=CC=C1C1=NC(C(N)=O)=C(C=2C=CC=CC=2)O1 JCNYVYGICSWKQM-UHFFFAOYSA-N 0.000 claims 3
- AHLPYPYPMMOUDM-UHFFFAOYSA-N 2-phenyl-5-(3,4,5-trimethoxyphenyl)-1,3-oxazole-4-carboxamide Chemical compound COC1=C(OC)C(OC)=CC(C2=C(N=C(O2)C=2C=CC=CC=2)C(N)=O)=C1 AHLPYPYPMMOUDM-UHFFFAOYSA-N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- JUOPGNVRTKZCPM-UHFFFAOYSA-N 2,4-diphenyl-1h-imidazole-5-carboxamide Chemical compound NC(=O)C=1N=C(C=2C=CC=CC=2)NC=1C1=CC=CC=C1 JUOPGNVRTKZCPM-UHFFFAOYSA-N 0.000 claims 2
- RGFVVYIVBCLQJQ-UHFFFAOYSA-N 2-(4-fluorophenyl)-4-(4-methoxyphenyl)-1h-imidazole-5-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=C(C(N)=O)N=C(C=2C=CC(F)=CC=2)N1 RGFVVYIVBCLQJQ-UHFFFAOYSA-N 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 2
- QJBYSTKTNPHHEY-UHFFFAOYSA-N 2-phenyl-5-thiophen-2-yl-1h-imidazole-4-carboxamide Chemical compound NC(=O)C=1N=C(C=2C=CC=CC=2)NC=1C1=CC=CS1 QJBYSTKTNPHHEY-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 102000003989 Aurora kinases Human genes 0.000 claims 2
- 108090000433 Aurora kinases Proteins 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 238000003763 carbonization Methods 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Chemical group 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 229930192474 thiophene Natural products 0.000 claims 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 229910052789 astatine Inorganic materials 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91719107P | 2007-05-10 | 2007-05-10 | |
| GB0709031.9 | 2007-05-10 | ||
| GBGB0709031.9A GB0709031D0 (en) | 2007-05-10 | 2007-05-10 | Pharmaceutical compounds |
| US60/917,191 | 2007-05-10 | ||
| US98727307P | 2007-11-12 | 2007-11-12 | |
| US60/987,273 | 2007-11-12 | ||
| PCT/GB2008/001612 WO2008139161A1 (en) | 2007-05-10 | 2008-05-09 | Oxazole tyrosine kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010526800A JP2010526800A (ja) | 2010-08-05 |
| JP2010526800A5 true JP2010526800A5 (cg-RX-API-DMAC10.html) | 2011-06-23 |
| JP5555620B2 JP5555620B2 (ja) | 2014-07-23 |
Family
ID=38219198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506999A Active JP5555620B2 (ja) | 2007-05-10 | 2008-05-09 | オキサゾールチロシンキナーゼ阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8378095B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2170849B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5555620B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN101796038B (cg-RX-API-DMAC10.html) |
| GB (1) | GB0709031D0 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2008139161A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3838903B1 (en) | 2005-12-13 | 2023-11-22 | Incyte Holdings Corporation | Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| CN101932582B (zh) | 2007-06-13 | 2013-09-25 | 因塞特公司 | 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐 |
| EP2250160B1 (en) | 2008-01-25 | 2015-11-11 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
| US8420695B2 (en) * | 2008-07-09 | 2013-04-16 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| GB0820819D0 (en) * | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9139589B2 (en) | 2009-01-30 | 2015-09-22 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| US8524751B2 (en) | 2009-03-09 | 2013-09-03 | GlaxoSmithKline Intellecutual Property Development | 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases |
| WO2010127152A2 (en) * | 2009-04-29 | 2010-11-04 | Irm Llc | Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors |
| ES2876933T3 (es) | 2009-04-30 | 2021-11-15 | Glaxo Group Ltd | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas |
| RS59632B1 (sr) | 2009-05-22 | 2020-01-31 | Incyte Holdings Corp | 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori |
| US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| ME02386B (me) | 2010-03-10 | 2016-09-20 | Incyte Holdings Corp | Derivati piperidin-4-il azetidina kao inhibitori jak1 |
| NZ603686A (en) | 2010-05-21 | 2014-11-28 | Incyte Corp | Topical formulation for a jak inhibitor |
| NZ604035A (en) | 2010-06-04 | 2015-02-27 | Albany Molecular Res Inc | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| US8796268B2 (en) | 2010-08-11 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9062038B2 (en) | 2010-08-11 | 2015-06-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2012021615A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9326987B2 (en) | 2010-09-08 | 2016-05-03 | Glaxo Group Limited | Indazole derivatives for use in the treatment of influenza virus infection |
| AU2011316016A1 (en) | 2010-10-13 | 2013-05-30 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
| TW201249845A (en) | 2010-11-19 | 2012-12-16 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| US9150559B2 (en) | 2011-05-19 | 2015-10-06 | The Board Of Trustees Of The Leland Stanford Junior University | Anti-proliferative compounds and methods for using the same |
| KR20140040819A (ko) | 2011-06-20 | 2014-04-03 | 인사이트 코포레이션 | Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체 |
| JP5792128B2 (ja) | 2011-07-29 | 2015-10-07 | 富士フイルム株式会社 | １，５−ナフチリジン誘導体又はその塩 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| US20130165483A1 (en) * | 2011-12-23 | 2013-06-27 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| GB201202027D0 (en) * | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| US20130231340A1 (en) * | 2012-03-02 | 2013-09-05 | Sareum Limited | Pharmaceutical compounds |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| US10166191B2 (en) | 2012-11-15 | 2019-01-01 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
| DK2964650T3 (en) | 2013-03-06 | 2019-02-11 | Incyte Holdings Corp | PROCEDURES AND INTERMEDIATES FOR THE MANUFACTURE OF A JAK INHIBITOR |
| SI3030227T1 (sl) | 2013-08-07 | 2020-08-31 | Incyte Corporation | Dozirne oblike s podaljšanim sproščanjem za inhibitor JAK1 |
| KR102191084B1 (ko) | 2013-09-03 | 2020-12-15 | 사름 리미티드 | 약제학적 화합물 |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| US10000474B2 (en) | 2014-11-11 | 2018-06-19 | Musc Foundation For Research Development | Histone deacetylase inhibitors and uses thereof |
| EP3053920B1 (en) * | 2015-02-05 | 2020-04-08 | AB Science | Compounds with anti-tumoral activity |
| CN104974095B (zh) * | 2015-06-30 | 2017-09-15 | 浙江大学 | 2,4,5‑多取代咪唑类化合物及制备方法 |
| CN105601580B (zh) * | 2015-11-29 | 2017-11-14 | 陈玉玲 | 一种噁唑类医药中间体化合物的合成方法 |
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| WO2018217766A1 (en) | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| LT3746429T (lt) | 2018-01-30 | 2022-05-10 | Incyte Corporation | (1-(3-fluor-2-(trifluormetil)izonikotinil)piperidin-4-ono) gamybos būdai |
| US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
| US11472781B2 (en) | 2018-02-21 | 2022-10-18 | Southern Research Institute | 2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases |
| MY206999A (en) | 2018-03-30 | 2025-01-23 | Incyte Corp | Treatment of hidradenitis suppurativa using jak inhibitors |
| WO2019222497A1 (en) | 2018-05-17 | 2019-11-21 | Southern Research Institute | 2,5-aryl-thiazole analogs for the treatment of neurodegenerative diseases |
| GB201816369D0 (en) * | 2018-10-08 | 2018-11-28 | Sareum Ltd | Pharmaceutical compounds |
| JP2022537877A (ja) | 2019-04-30 | 2022-08-31 | セルジーン コーポレイション | アプレミラストおよびｔｙｋ２阻害剤を含む併用療法 |
| GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794096A (fr) | 1972-08-07 | 1973-05-16 | Lepetit Spa | Oxazoles 2,4,5-trisubstitues et leur preparation |
| JPS6155456A (ja) | 1984-08-24 | 1986-03-19 | Toyota Motor Corp | 車輌用自動変速機のアイドル運転時制御方法 |
| JPH0753716B2 (ja) | 1986-07-02 | 1995-06-07 | 吉富製薬株式会社 | イミダゾ−ルカルボキサミド誘導体 |
| JPH0770133B2 (ja) | 1986-12-19 | 1995-07-31 | 三菱電機株式会社 | ヘツド支持機構 |
| JPH06310767A (ja) | 1993-04-26 | 1994-11-04 | Nec Corp | 寒剤容器の断熱支持構造 |
| DE19653355A1 (de) | 1996-12-20 | 1998-06-25 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung |
| GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| EE200200715A (et) * | 2000-06-28 | 2004-08-16 | Astrazeneca Ab | Asendatud kinasoliini derivaadid ja nende kasutamine inhibiitoritena |
| CN101307046B (zh) * | 2000-10-30 | 2012-08-15 | 詹森药业有限公司 | 三肽酶抑制剂 |
| JP4570955B2 (ja) * | 2002-07-09 | 2010-10-27 | バーテクス ファーマスーティカルズ インコーポレイテッド | プロテインキナーゼ阻害活性を持つイミダゾール類 |
| JP2006528631A (ja) * | 2003-07-24 | 2006-12-21 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
| US7718676B2 (en) | 2003-10-23 | 2010-05-18 | Ab Science | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors |
| GB0504753D0 (en) * | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| WO2007043400A1 (ja) * | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | 含窒素芳香族複素環化合物およびそれを含有する医薬組成物 |
| DK200600313A (da) | 2006-03-03 | 2006-03-13 | Novo Nordisk As | Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor |
| WO2007131953A1 (en) | 2006-05-12 | 2007-11-22 | Ab Science | A new process for the synthesis of 2-aminoxazole compounds |
| WO2008024980A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
-
2007
- 2007-05-10 GB GBGB0709031.9A patent/GB0709031D0/en not_active Ceased
-
2008
- 2008-05-09 CN CN200880024256.9A patent/CN101796038B/zh active Active
- 2008-05-09 EP EP08750551.7A patent/EP2170849B1/en active Active
- 2008-05-09 WO PCT/GB2008/001612 patent/WO2008139161A1/en not_active Ceased
- 2008-05-09 JP JP2010506999A patent/JP5555620B2/ja active Active
- 2008-05-09 US US12/599,653 patent/US8378095B2/en active Active
-
2012
- 2012-12-05 US US13/705,659 patent/US20130102592A1/en not_active Abandoned
-
2014
- 2014-06-03 US US14/294,263 patent/US8921544B2/en active Active
- 2014-10-31 US US14/529,902 patent/US9187465B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526800A5 (cg-RX-API-DMAC10.html) | ||
| RU2386620C2 (ru) | Производные пиридазин-3(2н)-она и их применение в качестве ингибиторов фдэ4 | |
| JP2016536364A5 (cg-RX-API-DMAC10.html) | ||
| RU2386622C2 (ru) | Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы | |
| JP2016536363A5 (cg-RX-API-DMAC10.html) | ||
| JP2008525417A5 (cg-RX-API-DMAC10.html) | ||
| RU2338745C1 (ru) | ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| JP2019514874A5 (cg-RX-API-DMAC10.html) | ||
| RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
| HRP20192274T1 (hr) | Novi derivati oktahidro-pirolo[3,4−c]-pirola i njihovi analozi kao inhibitori autotaksina | |
| JP2017502940A5 (cg-RX-API-DMAC10.html) | ||
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| CO6231028A2 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
| JP2015523383A5 (cg-RX-API-DMAC10.html) | ||
| AR075022A1 (es) | Derivados oxadiazole como agonistas de los receptores de esfingosina-1-fosfato (s1p1) | |
| RU2017125025A (ru) | Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk | |
| JP2018524338A5 (cg-RX-API-DMAC10.html) | ||
| AR092955A1 (es) | Antagonistas de receptores de orexina los cuales son derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)-pirrolidin-1-il]-metanona | |
| JP2004175807A5 (cg-RX-API-DMAC10.html) | ||
| JP2011502958A5 (cg-RX-API-DMAC10.html) | ||
| JP2015520140A5 (cg-RX-API-DMAC10.html) | ||
| JP2006500348A5 (cg-RX-API-DMAC10.html) | ||
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| JP2006517220A5 (cg-RX-API-DMAC10.html) | ||
| JP2009511490A5 (cg-RX-API-DMAC10.html) |